1. have cancer; or have other serious chronic diseases such as uncontrolled asthma, diabetes, liver and kidney disease, thyroid disease, convulsions, epilepsy and other neurological/psychiatric disorders. 2. have been diagnosed with congenital or acquired immunodeficiency, hiv infection, lymphoma, leukaemia or other autoimmune disease; 3. those who are allergic to any component of the experimental vaccine have had a history of severe vaccine allergic reaction in the past. 4. history of sars or mers or sars-cov-2 infection/illness within 3 months. 5. patients with more serious cardiovascular diseases, such as arrhythmia, conduction block, myocardial infarction, and severe hypertension that cannot be controlled by drugs. 6. congenital or acquired angioedema/neuroedema. 7. urticaria in the year prior to receiving the experimental vaccine. 8. asplenia or functional asplenia. 9. thrombocytopenia or other clotting disorders (which may cause intramuscular injection contraindications). 10. needle fainter. 11. immunosuppressive therapy, antiallergy therapy, cytotoxic therapy, and inhaled corticosteroids (excluding corticosteroid spray for allergic rhinitis and topical corticosteroids for acute non-concurrent dermatitis) for 14 or more days within 6 months prior to receiving the experimental vaccine. 12. received blood products within 3 months prior to receiving the trial vaccine. 13. received other investigational drugs within 1 month prior to receiving the experimental vaccine. 14. received subunit or inactivated vaccine within 14 days or live attenuated vaccine within 1 month prior to receiving the experimental vaccine. 15. are receiving anti-tb treatment. 16. medical, psychological, social or other conditions that, in the investigator's judgment, are inconsistent with the protocol or affect the subject's signing of informed consent.

1. have cancer; or have other serious chronic diseases such as uncontrolled asthma, diabetes, liver and kidney disease, thyroid disease, convulsions, epilepsy and other neurological/psychiatric disorders. 2. have been diagnosed with congenital or acquired immunodeficiency, hiv infection, lymphoma, leukaemia or other autoimmune disease; 3. those who are allergic to any component of the experimental vaccine have had a history of severe vaccine allergic reaction in the past. 4. history of sars or mers or sars-cov-2 infection/illness within 3 months. 5. patients with more serious cardiovascular diseases, such as arrhythmia, conduction block, myocardial infarction, and severe hypertension that cannot be controlled by drugs. 6. congenital or acquired angioedema/neuroedema. 7. urticaria in the year prior to receiving the experimental vaccine. 8. asplenia or functional asplenia. 9. thrombocytopenia or other clotting disorders (which may cause intramuscular injection contraindications). 10. needle fainter. 11. immunosuppressive therapy, antiallergy therapy, cytotoxic therapy, and inhaled corticosteroids (excluding corticosteroid spray for allergic rhinitis and topical corticosteroids for acute non-concurrent dermatitis) for 14 or more days within 6 months prior to receiving the experimental vaccine. 12. received blood products within 3 months prior to receiving the trial vaccine. 13. received other investigational drugs within 1 month prior to receiving the experimental vaccine. 14. received subunit or inactivated vaccine within 14 days or live attenuated vaccine within 1 month prior to receiving the experimental vaccine. 15. are receiving anti-tb treatment. 16. medical, psychological, social or other conditions that, in the investigator's judgment, are inconsistent with the protocol or affect the subject's signing of informed consent.

have cancer; or have other serious chronic diseases such as uncontrolled asthma, diabetes, liver and kidney disease, thyroid disease, convulsions, epilepsy and other neurological/psychiatric disorders. have been diagnosed with congenital or acquired immunodeficiency, hiv infection, lymphoma, leukaemia or other autoimmune disease; those who are allergic to any component of the experimental vaccine have had a history of severe vaccine allergic reaction in the past. history of sars or mers or sars-cov-2 infection/illness within 3 months. patients with more serious cardiovascular diseases, such as arrhythmia, conduction block, myocardial infarction, and severe hypertension that cannot be controlled by drugs. congenital or acquired angioedema/neuroedema. urticaria in the year prior to receiving the experimental vaccine. asplenia or functional asplenia. thrombocytopenia or other clotting disorders (which may cause intramuscular injection contraindications). needle fainter. immunosuppressive therapy, antiallergy therapy, cytotoxic therapy, and inhaled corticosteroids (excluding corticosteroid spray for allergic rhinitis and topical corticosteroids for acute non-concurrent dermatitis) for 14 or more days within 6 months prior to receiving the experimental vaccine. received blood products within 3 months prior to receiving the trial vaccine. received other investigational drugs within 1 month prior to receiving the experimental vaccine. received subunit or inactivated vaccine within 14 days or live attenuated vaccine within 1 month prior to receiving the experimental vaccine. are receiving anti-tb treatment. medical, psychological, social or other conditions that, in the investigator's judgment, are inconsistent with the protocol or affect the subject's signing of informed consent.

have cancer; or have other serious chronic diseases such as uncontrolled asthma, diabetes, liver and kidney disease, thyroid disease, convulsions, epilepsy and other neurological/psychiatric disorders. have been diagnosed with congenital or acquired immunodeficiency, hiv infection, lymphoma, leukaemia or other autoimmune disease; those who are allergic to any component of the experimental vaccine have had a history of severe vaccine allergic reaction in the past. history of sars or mers or sars-cov-2 infection/illness within 3 months. patients with more serious cardiovascular diseases, such as arrhythmia, conduction block, myocardial infarction, and severe hypertension that cannot be controlled by drugs. congenital or acquired angioedema/neuroedema. urticaria in the year prior to receiving the experimental vaccine. asplenia or functional asplenia. thrombocytopenia or other clotting disorders (which may cause intramuscular injection contraindications). needle fainter. immunosuppressive therapy, antiallergy therapy, cytotoxic therapy, and inhaled corticosteroids (excluding corticosteroid spray for allergic rhinitis and topical corticosteroids for acute non-concurrent dermatitis) for 14 or more days within 6 months prior to receiving the experimental vaccine. received blood products within 3 months prior to receiving the trial vaccine. received other investigational drugs within 1 month prior to receiving the experimental vaccine. received subunit or inactivated vaccine within 14 days or live attenuated vaccine within 1 month prior to receiving the experimental vaccine. are receiving anti-tb treatment. medical, psychological, social or other conditions that, in the investigator's judgment, are inconsistent with the protocol or affect the subject's signing of informed consent.